Stock Analysis
- Denmark
- /
- Medical Equipment
- /
- CPSE:EMBLA
Embla Medical hf Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Embla Medical hf (CPH:EMBLA) Second Quarter 2024 Results
Key Financial Results
- Revenue: US$216.7m (up 7.6% from 2Q 2023).
- Net income: US$19.9m (up 26% from 2Q 2023).
- Profit margin: 9.2% (up from 7.8% in 2Q 2023). The increase in margin was driven by higher revenue.
- EPS: US$0.047 (up from US$0.038 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Embla Medical hf EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) exceeded analyst estimates by 5.1%.
Looking ahead, revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Europe.
Performance of the market in Denmark.
The company's shares are up 4.2% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Embla Medical hf, and understanding this should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if Embla Medical hf might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About CPSE:EMBLA
Embla Medical hf
Provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.
Proven track record and fair value.